About Nexelis

A Legacy of Scientific Excellence and the Drive to Find Solutions

A multinational powerhouse with unparalleled expertise in immunology.

In Canada, we emerged from a GSK spin out as NEOMED-LABS with extensive knowledge and a pharma mindset. In the United States, we grew from a University of Washington research unit to earn wide respect as Pacific Biomarkers. In Europe, we expanded our clinical bioanalytical services with the acquisition of GSK Marburg. More recently, we were joined by PAIRimmune, a highly specialized in vivo lab; the renowned immunology specialists at ImmunXperts; and bioanalytical CRO, AIT Bioscience. These hand-picked entities share scientific discipline, acute problem-solving capabilities, and the will to deliver.

We know how much you value collaboration, flexibility, and quality. Our deep bench of scientists, advanced technology platforms, and international network of laboratories provide the biopharmaceutical industry with translational solutions from discovery through late stage clinical development. Together, our legacy companies have the years of experience and state-of-the-art technologies to support your study.

Leading specialty laboratory with best-in-class capabilities in assay and biomarker development, advanced bioanalytical testing and translational immunology

Recognized by leaders in the COVID-19 field as the reference assay development and testing company for vaccines


World leader in advanced lab testing for vaccine development

Unrivaled expertise in immunology, and in particular, infectious diseases, oncologic and metabolic diseases

State-of-the-art facilities with 150,000 sq. ft. of lab space worldwide

Partner of choice to leading pharmaceutical, innovative biotechnology, prestigious nongovernment and government organizations

ViE Award for Best Central/Specialty Laboratory, 2021

Nexelis is the winner of Terrapinn’s 2021 Vaccine Industry Excellence (ViE) Award for Best Central/Specialty Laboratory.

History of Nexelis

Our company was born from a series of strategic additions designed to provide our clients with the services they need. The common denominator in all these legacy companies is a combination of scientific excellence, agile thinking, and the drive to get things done.